Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, single centre dose-escalation phase I trial of AEOL-10150 in healthy volunteers.

Next Previous
Trial Profile

An open-label, single centre dose-escalation phase I trial of AEOL-10150 in healthy volunteers.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AEOL 10150 (Primary)
  • Indications Acute radiation syndrome
  • Focus Adverse reactions

Most Recent Events

  • 23 Mar 2017 According to an Aeolus Pharmaceuticals Inc media release, first 6 patients have completed dosing. A total of 9 patients will receive a single injection during this study, which is scheduled to be completed during the 2nd quarter of 2017
  • 22 Feb 2017 According to an Aeolus Pharmaceuticals Inc media release, the data from this study will be included in the Company's pre-Emergency Use Authorization application in Lung-ARS and will also be used to support the IPF and radiation therapy indications, as well as the use of AEOL 10150 as a medical countermeasure against lung damage from exposure to sulfur mustard gas.
  • 22 Feb 2017 Status changed from planning to recruiting, according to an Aeolus Pharmaceuticals Inc media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top